Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

NCT04481282 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT04481282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04481282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
July 8, 2020
Completion date
July 31, 2021
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia